Table 1 Comparison of urodynamic parameters and IPSS/QoL at V1a, V2b and V3c

From: Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study

 

V1

V2

V3

P-value

    

V1 vs V2

V1 vs V3

IPSS

15.60±7.79

11.29±5.77

9.01±4.86

<0.001

<0.001

QoL

3.22±0.89

2.86±0.90

2.42±0.96

0.001

<0.001

Qmax (ml s−1)

14.54±3.26

14.42±3.35

14.55±3.17

0.098

0.472

PVR (ml)

22.10±28.75

17.66±15.07

18.71±16.65

0.229

0.343

  1. Abbreviations: IPSS, international prostate symptom score; PVR, post-voiding residual urine volume; Qmax, peak urine flow rate; QoL, quality of life.
  2. aAt the start of the study.
  3. b4 weeks after the initial administration of the drug.
  4. c8 weeks after the initial administration of the drug.
Back to article page